265 related articles for article (PubMed ID: 29099504)
1. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.
Griewank KG; Wiesner T; Murali R; Pischler C; Müller H; Koelsche C; Möller I; Franklin C; Cosgarea I; Sucker A; Schadendorf D; Schaller J; Horn S; Brenn T; Mentzel T
Mod Pathol; 2018 Mar; 31(3):418-428. PubMed ID: 29099504
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Griewank KG; Schilling B; Murali R; Bielefeld N; Schwamborn M; Sucker A; Zimmer L; Hillen U; Schaller J; Brenn T; Schadendorf D; Mentzel T
Mod Pathol; 2014 Apr; 27(4):502-8. PubMed ID: 24030750
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden.
Ak M; Kahraman A; Arnold FM; Turko P; Levesque MP; Zoche M; Ramelyte E; Dummer R
Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34202213
[TBL] [Abstract][Full Text] [Related]
4. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Ihle MA; Pütz K; Tantcheva-Poor I; Mauch C; Büttner R; Quaas A
Oncotarget; 2016 Apr; 7(16):21763-74. PubMed ID: 26943575
[TBL] [Abstract][Full Text] [Related]
5. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
[TBL] [Abstract][Full Text] [Related]
6. Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Quaas A; Mauch C; Merkelbach-Bruse S; Büttner R; Emberger M; Wobser M; Rüsseler V; Pütz K; Binot E; Rehker J; Budczies J; Ihle MA
Oncotarget; 2017 Dec; 8(65):109457-109467. PubMed ID: 29312620
[TBL] [Abstract][Full Text] [Related]
7. Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma.
Miller K; Goodlad JR; Brenn T
Am J Surg Pathol; 2012 Sep; 36(9):1317-26. PubMed ID: 22510760
[TBL] [Abstract][Full Text] [Related]
8. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
Pérot G; Chibon F; Montero A; Lagarde P; de Thé H; Terrier P; Guillou L; Ranchère D; Coindre JM; Aurias A
Am J Pathol; 2010 Oct; 177(4):2080-90. PubMed ID: 20884963
[TBL] [Abstract][Full Text] [Related]
9. Pleomorphic dermal sarcoma in a man with HIV: report with next-generation sequencing analysis and review of the atypical fibroxanthoma/pleomorphic dermal sarcoma spectrum.
Chen SX; Eichenfield DZ; Orme C; Hinds B
Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045146
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype.
Koelsche C; Stichel D; Griewank KG; Schrimpf D; Reuss DE; Bewerunge-Hudler M; Vokuhl C; Dinjens WNM; Petersen I; Mittelbronn M; Cuevas-Bourdier A; Buslei R; Pfister SM; Flucke U; Mechtersheimer G; Mentzel T; von Deimling A
Clin Sarcoma Res; 2019; 9():2. PubMed ID: 30809375
[TBL] [Abstract][Full Text] [Related]
11. Relation Between Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: Histopathologic Features and Review of the Literature.
Iglesias-Pena N; Martínez-Campayo N; López-Solache L
Actas Dermosifiliogr (Engl Ed); 2021 May; 112(5):392-405. PubMed ID: 33301761
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of melanocytic and myofibroblastic markers and their molecular correlation in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Mauch C; Buettner R; Quaas A
J Cutan Pathol; 2018 Dec; 45(12):880-885. PubMed ID: 30155964
[TBL] [Abstract][Full Text] [Related]
13. Atypical fibroxanthoma with pseudoangiomatous features: a histological and immunohistochemical mimic of cutaneous angiosarcoma.
Thum C; Husain EA; Mulholland K; Hornick JL; Brenn T
Ann Diagn Pathol; 2013 Dec; 17(6):502-7. PubMed ID: 24080496
[TBL] [Abstract][Full Text] [Related]
14. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
15. Primary cardiac undifferentiated pleomorphic sarcoma is associated with TP53 mutation during lack of MDM2 amplification, and targeted sequencing analysis reveals potentially actionable targets.
Cui Y; Han L; Shang J; Fang W; Zhao M; Chen D; Liu H
Hum Pathol; 2022 May; 123():113-122. PubMed ID: 35181378
[TBL] [Abstract][Full Text] [Related]
16. Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma.
Lim SM; Cho SH; Hwang IG; Choi JW; Chang H; Ahn MJ; Park KU; Kim JW; Ko YH; Ahn HK; Cho BC; Nam BH; Chun SH; Hong JH; Kwon JH; Choi JG; Kang EJ; Yun T; Lee KW; Kim JH; Kim JS; Lee HW; Kim MK; Jung D; Kim JE; Keam B; Yun HJ; Kim S; Kim HR
Cancer Res Treat; 2019 Jan; 51(1):300-312. PubMed ID: 29747488
[TBL] [Abstract][Full Text] [Related]
17. Genomic analysis of metastatic cutaneous squamous cell carcinoma.
Li YY; Hanna GJ; Laga AC; Haddad RI; Lorch JH; Hammerman PS
Clin Cancer Res; 2015 Mar; 21(6):1447-56. PubMed ID: 25589618
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous undifferentiated pleomorphic sarcoma is a pleomorphic dermal sarcoma.
Cohen PR
Dermatol Online J; 2020 May; 26(5):. PubMed ID: 32621710
[TBL] [Abstract][Full Text] [Related]
19. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations and CDKN2A mutations/deletions are highly recurrent molecular alterations in the malignant progression of sinonasal papillomas.
Brown NA; Plouffe KR; Yilmaz O; Weindorf SC; Betz BL; Carey TE; Seethala RR; McHugh JB; Tomlins SA; Udager AM
Mod Pathol; 2021 Jun; 34(6):1133-1142. PubMed ID: 33203919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
